Connecting Medical Innovations to Patient Benefits: A Non-Small Cell Lung Cancer Case Study

Medical innovations possess the capacity to transform healthcare, changing how patients are diagnosed and treated. From antibiotics to advanced genomic medicine, the journey from discovery to practical application has consistently been lengthy and intricate. A significant obstacle in unlocking the full potential of these developments is the disconnect between scientific possibilities and real-world adoption in healthcare frameworks. Factors such as sluggish adoption rates, inefficient workflows, and obsolete methodologies cause delays, preventing patients from reaping the benefits of life-saving advancements.

A prime illustration of this phenomenon is found in the treatment of non-small cell lung cancer (NSCLC). The introduction of genomic testing and targeted therapies presents remarkable chances to enhance diagnosis and patient outcomes. Nonetheless, challenges like underutilization, inefficient processes, and systemic hold-ups hinder the widespread availability of these innovations.

The Potential of Targeted Therapy and Genomic Testing

Targeted therapy is an innovative method for cancer treatment that customizes therapeutic approaches based on the specific genetic mutations fueling a patient’s cancer. For NSCLC, genomic testing pinpoints biomarkers—crucial genetic alterations related to the condition. This information assists oncologists in formulating optimal treatment strategies, frequently matching diagnoses with highly specific, guideline-approved drugs.

In spite of this potential, the incorporation of genomic testing and targeted therapies into standard cancer care has encountered complications. Research indicates significant gaps in utilization and timing, issues that healthcare systems must promptly resolve if these advancements are to achieve widespread clinical acceptance.

—

Testing Inadequacies: A Significant Obstacle

Genomic testing serves as a crucial element for enabling targeted therapies for NSCLC. However, testing remains underutilized, resulting in numerous patients being either untested or insufficiently assessed. For instance, an internal evaluation of health plan members disclosed that 44% of NSCLC patients lacked documentation of undergoing biomarker testing. Even more alarming, retrospective research indicates that only 18% of patients received all the gene mutation tests recommended by the National Comprehensive Cancer Network (NCCN).

Why Is There Low Utilization of Genetic Tests?

Multiple factors contribute to the low rates of testing:
1. Dependence on Tissue Testing:
Conventional tissue sample testing—which necessitates surgical extraction—is invasive, time-consuming, and prone to logistical issues. Tissue tests may also fail to provide samples of adequate quality, especially in advanced or difficult-to-reach tumors.

2. Prolonged Result Turnaround:
Tissue testing typically requires weeks to yield results due to the multiple steps involved in sample extraction, transport, and analysis. This considerably delays the initiation of appropriate therapies.

3. Financial Obstacles:
Numerous patients confront steep out-of-pocket expenses for testing, while insurance coverage varies significantly based on the plan or provider network.

4. Health Disparities:
Testing rates differ across demographics, with racial and ethnic minorities—who are already disproportionately affected by lung cancer—having reduced access to genomic testing.

The Argument for Liquid Biopsy

A potential remedy for the underutilization of genetic testing lies in embracing liquid biomarker testing, commonly referred to as a liquid biopsy. Unlike standard tissue testing, liquid biopsies are noninvasive, leveraging a simple blood draw to capture and examine circulating tumor DNA. Key benefits include:
– Accelerated Results: Liquid biopsy results can be attained two to three weeks quicker than traditional techniques.
– Reduced Invasiveness: Liquid biopsies eliminate the necessity for surgical extractions or multiple tumor sampling.
– Increased Accessibility: The procedure is simpler, necessitates fewer healthcare personnel, and promotes broader applicability across varied healthcare environments.
– Equitable Opportunities: Liquid biopsies may help mitigate disparities by standardizing testing irrespective of practice type or location.

Enhancing the uptake of liquid biomarker testing could guarantee a greater number of patients receive accurate diagnoses, substantially improving the likelihood of appropriate targeted therapy.

—

The Delay Dilemma in Treatment

Even when testing occurs, the duration from diagnosis to treatment frequently proves excessive. In certain instances, NSCLC patients may experience delays of 40–60 days before therapy commences. This prolonged period is primarily a result of the fragmented process, which encompasses:
– Communication across numerous providers, laboratories, and health plans.
– Logistical hurdles, such as delays in test results and administrative clearances for prior authorizations (PAs).

Given the progressive nature of cancer, these delays impose a toll on patient outcomes and survival rates.

A Model to Reduce Delays

Innovative systems for lab values management (LVM) can tackle the challenges of delay. Here is an illustration of how an LVM-enhanced workflow could streamline the diagnostic and treatment process:
1. Automated Prior Authorization (PA): Following an NSCLC diagnosis, the provider gets an automatic approval from the health plan to request a liquid biopsy test.
2. Efficient Lab Testing: The test is processed by laboratories within the health plan.